Answers are grounded in this paper and cite their sources.
Conjugates of cytotoxic agents with RGD peptides (Arg-Gly-Asp) addressed to ανβ3, α5β1 and ανβ6 integrin receptors overexpressed by cancer cells, have recently gained attention as potential selective anticancer chemotherapeutics. In this review, the design and the development of RGD conjugates coupled to different small molecules including known cytotoxic drugs and natural products will be discussed.
No takes yet. Share an insight, caveat, or question.
Katsamakas et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: